Cytochrome P450 3A4 (CYP3A4)

Overview

Cytochrome P450 family 3 subfamily A member 4, commonly abbreviated CYP3A4, is a major human drug-metabolizing enzyme in the Cytochrome P450 (CYP) superfamily. It plays a central role in the oxidative metabolism of a wide range of endogenous compounds and xenobiotics, including many clinically used drugs. As a hepatic and intestinal enzyme, CYP3A4 is one of the most important determinants of drug clearance, interindividual variability in exposure, and susceptibility to drug–drug interactions.

Functionally, CYP3A4 operates within the broader Cytochrome P450 (CYP) catalytic system and requires electrons supplied by P450 oxidoreductase (POR) for its catalytic cycle. In biomedical research, CYP3A4 is frequently used as a marker of metabolic capacity and as a key target in studies of pharmacokinetics, enzyme inhibition, and drug safety. It is also closely studied alongside related enzymes such as CYP3A5, CYP2C19, CYP2B6, and CYP1A2, as well as transporters such as ABCB1, because these proteins collectively shape drug disposition and therapeutic response.

Recent Publications Summary

Recent publications on CYP3A4 focused on its role in drug metabolism, drug–drug interactions, and inhibition across both clinical and preclinical settings. A clinical pharmacokinetic study and updated physiologically based pharmacokinetic (PBPK) modeling found that the CYP3A4 inhibitor clarithromycin had only a minimal effect on siponimod exposure in healthy participants, with small increases in Cmax, AUClast, and AUCinf and no clinically relevant interaction; the revised model estimated a CYP3A4 fraction metabolized of 6.4% in the CYP2C911 genotype and predicted no clinically relevant interaction with moderate or strong CYP3A4 inhibitors across CYP2C9 genotypes 42364973Jun. In a separate clinical and in vitro evaluation, bemnifosbuvir was characterized as a weak inducer and a reversible and time-dependent inhibitor of CYP3A4, and coadministration with midazolam increased midazolam exposure in healthy participants, with the magnitude depending on dosing schedule and regimen 42053458Apr.

Several studies examined CYP3A4 in the context of drug disposition and metabolism in vitro. Donafenib metabolism was shown to depend primarily on CYP3A4, which catalyzed N-oxide formation in recombinant enzyme and inhibitor-based phenotyping assays; this was supported by increased exposure and half-life in Cyp3a1/2 knockout rats, and multiple CYP3A4 variants were reported to have reduced catalytic activity relative to CYP3A4.1 41687527Feb. Golvatinib was profiled in human and rat liver microsomes using UHPLC-MS/MS and UHPLC-Q-Orbitrap-HRMS, revealing faster turnover in rat microsomes than in human microsomes and identifying twelve metabolites, although the abstract does not specify CYP3A4 as the responsible enzyme 42210592May.

Other publications addressed CYP3A4 inhibition or prediction in broader translational and methodological contexts. A chitosan-based oral delivery system for doxorubicin incorporated purine nucleosides and silybin and was designed to enhance absorption through nucleoside transporter mediation while also inhibiting P-gp efflux and CYP3A4 metabolism, contributing to markedly increased oral bioavailability in vivo 42289209Jun. A HepaRG cell-based assay combined with phytochemical analysis was applied to Tinospora crispa stem extracts to assess quality, safety, and CYP3A4 inhibition potential in the context of herbal hepatotoxicity risk, though the abstract provided only the study rationale and analytical approach 41850439Mar. In addition, DeepCYP was introduced as a deep-learning web server for end-to-end CYP450 metabolic profiling across nine major isoforms, including CYP3A4, with improved ranking performance over existing tools and high-throughput batch processing capability 42152517May. A candidate-gene study in a Japanese cohort also investigated CYP3A-related polymorphisms, including CYP3A4, using the 4β-hydroxycholesterol/cholesterol ratio as a biomarker of CYP3A activity 42319470Jun.

What Changes, What Holds

1. Minimal CYP3A4 inhibition by clarithromycin does not materially alter siponimod exposure
REINFORCES The clinical and modeling data sharpen the baseline view of CYP3A4 as an important interaction pathway by showing that, for this substrate, even a recognized inhibitor produced only small exposure changes and no clinically relevant interaction. That does not weaken CYP3A4’s general importance; it instead suggests that the fraction of clearance routed through CYP3A4 can be modest for some drugs, so interaction risk remains substrate-specific rather than uniform. 42364973Jun

2. CYP3A4 can both induce and inhibit exposure depending on regimen, and variant activity may matter
REINFORCES Bemnifosbuvir adds another example of CYP3A4 as a practical determinant of drug disposition, but the main takeaway is not a new biological role. It reinforces the enzyme’s centrality in interaction studies while showing that a single agent may produce mixed effects on CYP3A4 function, with consequences that depend on dosing schedule. The variant-related findings are consistent with the baseline emphasis on interindividual variability, though they do not settle how broadly that applies. 42053458Apr

3. Donafenib appears to rely on CYP3A4 as a major metabolic route
REINFORCES The metabolism work strengthens the established account of CYP3A4 as a key oxidative enzyme for xenobiotics and drugs. Rather than changing what CYP3A4 is understood to do, it adds another substrate whose disposition is shaped primarily by this isoform and by reduced-function variants. The knockout-rat and variant data are supportive but still preclinical, so they extend the substrate list more than they redefine the enzyme’s role. 41687527Feb

4. Metabolite profiling can map CYP3A4-related disposition without proving enzyme responsibility
METHOD The golvatinib study mainly changes how CYP3A4-adjacent metabolism is investigated: high-resolution mass spectrometry and microsomal profiling improve metabolite detection and turnover mapping, but the abstract does not assign the observed metabolism to CYP3A4. That leaves the baseline untouched while illustrating a more detailed analytical workflow for future phenotyping and interaction work. 42210592May

5. Oral delivery systems can be engineered to suppress CYP3A4-mediated first-pass loss
NEW DIRECTION A delivery strategy that deliberately inhibits CYP3A4 shifts the enzyme from being only a clearance determinant to a barrier that can be pharmacologically bypassed to raise oral bioavailability. The baseline covers CYP3A4 as a drug-metabolizing enzyme, but not this formulation-level use against it. This is a translational application rather than a contradiction, and it suggests CYP3A4 can be targeted alongside transporters in oral drug design. 42289209Jun

6. Herbal safety assessment is increasingly tied to CYP3A4 inhibition screening
METHOD The Tinospora crispa work does not establish a new biological role for CYP3A4; it shows how CYP3A4 inhibition testing is being folded into quality and hepatotoxicity assessment pipelines for botanicals. That keeps the baseline intact while expanding the enzyme’s use as a screening readout in safety-oriented translational assays. 41850439Mar

7. Deep learning now offers a broader way to predict CYP3A4 metabolism alongside other isoforms
METHOD DeepCYP changes the study of CYP3A4 by improving prediction and throughput across multiple CYP450s, including this one, rather than changing what CYP3A4 does biologically. The baseline’s account of CYP3A4 as a major metabolic enzyme stands; what changes is the analytical capacity to profile it at scale and compare it with related isoforms in silico. 42152517May

8. Circulating 4β-hydroxycholesterol remains a practical biomarker for CYP3A activity in human studies
REINFORCES The candidate-gene study supports the baseline’s framing of CYP3A4 as a marker of metabolic capacity by using a recognized activity biomarker in a human cohort. It does not redefine CYP3A4, but it reinforces its role in pharmacogenetic and phenotyping work, while leaving open how much of the signal is attributable to CYP3A4 versus related CYP3A enzymes. 42319470Jun

Overview update candidates: clarithromycin-siponimod interaction appears clinically minimal for this substrate; bemnifosbuvir can modulate CYP3A4 in both inhibitory and inductive directions; donafenib is primarily metabolized by CYP3A4; formulation strategies can intentionally inhibit CYP3A4 to improve oral bioavailability.